Oruka Therapeutics annual net income
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Oruka Therapeutics Net Income Growth & History (ORKA)
Oruka Therapeutics's net income was −$105.4M for fiscal 2025.
View full Oruka Therapeutics company overviewOruka Therapeutics annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$105.4M | −$21.7M | — |
| 2024 | 2024-12-31 | −$83.7M | −$78.4M | — |
| 2023 | 2023-12-31 | −$5.3M | $4.6M | — |
| 2022 | 2022-12-31 | −$9.9M | $9.4M | — |
| 2021 | 2021-12-31 | −$19.3M | −$9.6M | — |
| 2020 | 2020-12-31 | −$9.7M | −$4.3M | — |
| 2019 | 2019-12-31 | −$5.5M | $2.5M | — |
| 2018 | 2018-12-31 | −$7.9M | $10.6M | — |
| 2017 | 2017-12-31 | −$18.5M | −$2.0M | — |
| 2016 | 2016-12-31 | −$16.4M | −$5.0M | — |
| 2015 | 2015-12-31 | −$11.4M | −$1.8M | — |
| 2014 | 2014-12-31 | −$9.7M | −$2.8M | — |
| 2013 | 2013-12-31 | −$6.9M | −$2.6M | — |
| 2012 | 2012-12-31 | −$4.3M | $1.0M | — |
| 2011 | 2011-12-31 | −$5.4M | $3.1M | — |
| 2010 | 2010-12-31 | −$8.4M | $718,000 | — |
| 2009 | 2009-12-31 | −$9.1M | $10.3M | — |
| 2008 | 2008-12-31 | −$19.4M | −$5.4M | — |
| 2007 | 2007-12-31 | −$14.0M | −$8.8M | — |
| 2006 | 2006-12-31 | −$5.2M | −$3.8M | — |
| 2005 | 2005-12-31 | −$1.5M | −$948,000 | — |
| 2004 | 2004-12-31 | −$511,000 | — | — |
Oruka Therapeutics quarterly net income
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$41.2M | −$16.6M | — |
| Q1 2026 | 2026-03-31 | −$31.8M | −$10.8M | — |
| Q4 2025 | 2025-12-31 | −$29.6M | $1.3M | — |
| Q3 2025 | 2025-09-30 | −$30.3M | −$1.7M | — |
| Q2 2025 | 2025-06-30 | −$24.6M | −$2.3M | — |
| Q1 2025 | 2025-03-31 | −$21.0M | −$19.0M | — |
| Q4 2024 | 2024-12-31 | −$30.8M | −$29.8M | — |
| Q3 2024 | 2024-09-30 | −$28.6M | −$27.2M | — |
| Q2 2024 | 2024-06-30 | −$22.2M | −$20.8M | — |
| Q1 2024 | 2024-03-31 | −$2.0M | −$663,000 | — |
| Q4 2023 | 2023-12-31 | −$1.1M | $85,000 | — |
| Q3 2023 | 2023-09-30 | −$1.4M | $909,000 | — |
| Q2 2023 | 2023-06-30 | −$1.5M | $1.7M | — |
| Q1 2023 | 2023-03-31 | −$1.3M | $1.9M | — |
| Q4 2022 | 2022-12-31 | −$1.2M | $4.5M | — |
| Q3 2022 | 2022-09-30 | −$2.3M | $2.4M | — |
| Q2 2022 | 2022-06-30 | −$3.1M | $1.7M | — |
| Q1 2022 | 2022-03-31 | −$3.3M | $828,000 | — |
| Q4 2021 | 2021-12-31 | −$5.7M | −$551,000 | — |
| Q3 2021 | 2021-09-30 | −$4.7M | −$2.7M | — |
| Q2 2021 | 2021-06-30 | −$4.8M | −$3.5M | — |
| Q1 2021 | 2021-03-31 | −$4.1M | −$2.8M | — |
| Q4 2020 | 2020-12-31 | −$5.1M | −$3.9M | — |
| Q3 2020 | 2020-09-30 | −$2.0M | −$835,000 | — |
| Q2 2020 | 2020-06-30 | −$1.3M | $134,000 | — |
| Q1 2020 | 2020-03-31 | −$1.3M | $344,000 | — |
| Q4 2019 | 2019-12-31 | −$1.2M | $263,000 | — |
| Q3 2019 | 2019-09-30 | −$1.2M | $437,000 | — |
| Q2 2019 | 2019-06-30 | −$1.4M | $680,000 | — |
| Q1 2019 | 2019-03-31 | −$1.7M | $1.1M | — |
| Q4 2018 | 2018-12-31 | −$1.5M | $2.7M | — |
| Q3 2018 | 2018-09-30 | −$1.6M | $2.8M | — |
| Q2 2018 | 2018-06-30 | −$2.1M | $3.4M | — |
| Q1 2018 | 2018-03-31 | −$2.7M | $1.6M | — |
| Q4 2017 | 2017-12-31 | −$4.2M | $47,000 | — |
| Q3 2017 | 2017-09-30 | −$4.4M | $226,000 | — |
| Q2 2017 | 2017-06-30 | −$5.5M | −$1.6M | — |
| Q1 2017 | 2017-03-31 | −$4.3M | −$691,000 | — |
| Q4 2016 | 2016-12-31 | −$4.2M | −$1.1M | — |
| Q3 2016 | 2016-09-30 | −$4.7M | −$1.8M | — |
| Q2 2016 | 2016-06-30 | −$3.9M | −$1.2M | — |
| Q1 2016 | 2016-03-31 | −$3.6M | −$903,000 | — |
| Q4 2015 | 2015-12-31 | −$3.2M | −$557,000 | — |
| Q3 2015 | 2015-09-30 | −$2.8M | −$530,000 | — |
| Q2 2015 | 2015-06-30 | −$2.7M | −$314,000 | — |
| Q1 2015 | 2015-03-31 | −$2.7M | −$355,000 | — |
| Q4 2014 | 2014-12-31 | −$2.6M | $335,000 | — |
| Q3 2014 | 2014-09-30 | −$2.3M | −$561,000 | — |
| Q2 2014 | 2014-06-30 | −$2.4M | −$1.2M | — |
| Q1 2014 | 2014-03-31 | −$2.4M | −$1.3M | — |
| Q4 2013 | 2013-12-31 | −$2.9M | −$2.1M | — |
| Q3 2013 | 2013-09-30 | −$1.7M | −$796,000 | — |
| Q2 2013 | 2013-06-30 | −$1.2M | −$53,000 | — |
| Q1 2013 | 2013-03-31 | −$1.1M | $336,000 | — |
| Q4 2012 | 2012-12-31 | −$840,000 | $790,000 | — |
| Q3 2012 | 2012-09-30 | −$927,000 | $895,000 | — |
| Q2 2012 | 2012-06-30 | −$1.1M | −$1.4M | — |
| Q1 2012 | 2012-03-31 | −$1.4M | $799,000 | — |
| Q4 2011 | 2011-12-31 | −$1.6M | — | — |
| Q3 2011 | 2011-09-30 | −$1.8M | $284,000 | — |
| Q2 2011 | 2011-06-30 | $294,000 | $2.6M | — |
| Q1 2011 | 2011-03-31 | −$2.2M | — | — |
| Q3 2010 | 2010-09-30 | −$2.1M | — | — |
| Q2 2010 | 2010-06-30 | −$2.3M | — | — |
Oruka Therapeutics net income trends
Over the last five fiscal years, Oruka Therapeutics's net income decreased from −$9.7M to −$105.4M, a change of −$95.7M. The latest reported quarter, Q2 2026, shows −$41.2M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oruka Therapeutics source filings ↗Community posts
Oruka’s psoriasis study supports planned Phase 3 trials after strong skin clearance
Oruka ($ORKA) reported positive 16-week results for ORKA-001 in the randomized Phase 2b EVERLAST-B psoriasis study. Among 46 patients assigned the highest dose, 61% achieved complete skin clearance, compared with none of 47 placebo recipien ...
